U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07174583) titled 'A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer' on Sept. 11.
Brief Summary: This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Small-cell Lung Cancer
Intervention:
DRUG: IDE849
IV administration
Recruitment Status: RECRUITING
Sponsor: IDEAYA Biosciences
Disclaimer: Curated by HT Syndication....